Clinical Response Articles & Analysis: Older
10 articles found
Preclinical drug discovery represents a critical phase in the development of new therapeutics. It is the process that bridges the gap between basic research and clinical testing, allowing for the evaluation of potential drug candidates in biological systems before they are tested in humans. Central to this phase is the use of appropriate disease models, which are essential for understanding the ...
One of the biggest challenges clinical data management faces is the sheer amount of data that needs to be processed. With more and more patient data becoming available, it can be difficult for CDM systems to keep up. In addition, many CDM systems are not user-friendly or interactive, making it difficult for users to get the most out of them. What challenges do clinical data management systems ...
ByClinion
Interleukin-2 (IL-2) is a 15kDa secretory protein with a 4-alpha-helical bundle structure. As a T-cell related growth factor, IL-2 can enhance the killing activity of NK cells and promote B cells to produce immunoglobulins. In addition, it aids in the development of regulatory T cells (Tregs), thereby producing peripheral T cell immune tolerance, as well as regulating the proliferation and ...
Summary In this Cell Patterns publication, Ozette co-founders and collaborators at the Cancer Immunotherapy Trials Network (CITN) outline a novel method of analysis of single cell data, FAUST, and validate the multiple potential applications. The paper tackles 2 important problems: 1) analysis of complex single cell datasets; 2) prediction of response to immunotherapy in cancer. Manual ...
This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). In the years following, researchers have explored the value of using MRD status to guide treatment in blood cancers – and the mounting ...
Strongyloides is an opportunistic pathogenic parasitic nematode. Adults parasitize in the small intestine of cats, dogs and humans. The larvae can invade lung, brain, liver, kidney and other tissues and organs, causing strongyloidiasis. The disease is mainly prevalent in warm and humid tropical and subtropical regions. In recent years, due to the continuous increase of HIV/AIDS infection rate in ...
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...
Obstructive sleep apnea (OSA) is a serious and life-threatening condition. Approximately 5.9 million adults are diagnosed with OSA, but as many as 23 million people are estimated to be dealing with OSA yet go undiagnosed. The impact on health can be significant, ranging from inconveniences to life-threatening illnesses. Obstructive sleep apnea can cause disrupted sleep for both OSA sufferers and ...
Abstract Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not ...